Eiger BioPharmaceuticals Inc EIGR:NASDAQ

Last Price$4.09NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22

Today's Change-0.08(1.92%)
Bid (Size)$3.91 (3)
Ask (Size)$4.11 (11)
Day Low / High$3.97 - 4.21
Volume302.1 K
 

View Biotechnology IndustryPeer Comparison as of 01/21/2022

 

Eiger BioPharmaceuticals Inc ( NASDAQ )

Price: $4.09
Change: -0.08 (1.92%)
Volume: 302.1 K
4:00PM ET 1/21/2022
 
 

Sesen Bio Inc ( NASDAQ )

Price: $0.71
Change: -0.01 (1.79%)
Volume: 2.1 M
4:00PM ET 1/21/2022
 
 

Solid Biosciences Inc ( NASDAQ )

Price: $1.28
Change: -0.06 (4.48%)
Volume: 777.5 K
4:00PM ET 1/21/2022
 
 

Syros Pharmaceuticals Inc ( NASDAQ )

Price: $2.18
Change: -0.08 (3.54%)
Volume: 421.5 K
4:00PM ET 1/21/2022
 
 

Savara Inc ( NASDAQ )

Price: $1.15
Change: -0.07 (5.74%)
Volume: 357.0 K
4:00PM ET 1/21/2022
 

Read more news Recent News

Eiger BioPharmaceuticals Enrolls First Patient for Late-Study of Potential Hepatitis D Treatment
4:38PM ET 12/21/2021 MT Newswires

Eiger BioPharmaceuticals (EIGR) said late Tuesday it enrolled the first patient for a phase 3 trial of its Peginterferon Lambda drug candidate in patients...

Eiger Biopharmaceuticals Says Data Monitoring Panel Backs Continuation of Late-Stage COVID-19 Trial
9:30AM ET 12/15/2021 MT Newswires

Eiger Biopharmaceuticals (EIGR) said Wednesday the data safety monitoring board recommended continuation of its late-stage trial of Peginterferon Lambda in...

-- Earnings Flash (EIGR) EIGER BIOPHARMACEUTICALS Posts Q3 Loss $-0.65
4:15PM ET 11/04/2021 MT Newswires

...

Eiger BioPharmaceuticals Completes Enrollment in Late-Stage Study of Lonafarnib for Hepatitis Delta Virus Infection
11:43AM ET 11/01/2021 MT Newswires

Eiger BioPharmaceuticals (EIGR) on Monday said that it has completed enrollment in the phase 3 D-LIVR study evaluating Lonafarnib for the treatment of...

Company Profile

Business DescriptionEiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA. View company web site for more details
Address2155 Park Boulevard
Palo Alto, California 94306
Phone+1.650.272.6138
Number of Employees18
Recent SEC Filing01/21/2022SC 13D
President, Chief Executive Officer & DirectorDavid A. Cory
Chief Financial OfficerSriram Ryali
Senior Vice President-Clinical DevelopmentIngrid C. Choong
Senior VP-Clinical & Development OperationsColin Hislop

Company Highlights

Price Open$4.14
Previous Close$4.17
52 Week Range$3.97 - 13.49
Market Capitalization$139.0 M
Shares Outstanding34.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.94
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-352.48%
Return on Equity-29.49%

Analyst Ratings as of 12/02/2021

Buy
4
Overweight
1
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset